Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Makes Post-Market Safety Evaluation Comprehensive For All NMEs, BLAs

Executive Summary

All new molecular entities and BLAs approved since Sept. 27, 2007, will be subject to the comprehensive post-market safety evaluation process that FDA pilot-tested during the past two years
Advertisement

Related Content

NME Safety Reviews Expected For Three More Drugs, With FDA Pilot Program Expansion
FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
Pilot Program Will Review First-Year Safety Data for Several NMEs

Topics

Advertisement
UsernamePublicRestriction

Register

PS051584

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel